Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (NCT07179380)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
Who can join: Review the eligibility criteria below.
Location: USA010 — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (145 Sites)
Showing the first 25 of 145 sites.
- USA010 — Los Angeles, California
- USA001 — Santa Barbara, California
- USA017 — Gainesville, Florida
- USA006 — Naples, Florida
- USA026 — St. Petersburg, Florida
- USA002 — Kansas City, Kansas
- USA005 — New York, New York
- USA015 — Cincinnati, Ohio
- USA003 — Bend, Oregon
- USA013 — Philadelphia, Pennsylvania
- USA008 — Richmond, Virginia
- ARG005 — Ciudad Autónoma de Buenos Aires, Buenos Aires
- ARG002 — CiudadAutonoma de Buenos Aires, Buenos Aires
- ARG003 — Río Cuarto, Córdoba Province
- ARG008 — San Miguel de Tucumán, Tucumán Province
- ARG004 — Córdoba,
- ARG001 — Córdoba,
- AUS001 — Camperdown, New South Wales
- AUS006 — Kingswood, New South Wales
- AUS005 — New Lambton Heights, New South Wales
- AUS003 — Westmead, New South Wales
- AUS002 — South Brisbane, Queensland
- AUT002 — Innsbruck,
- BEL002 — Leuven, Vlaams Brabant
- BEL001 — Anderlecht,
📞 Contact the Study Coordinator
Phone: (844) 446-7633
Email: medicalinformation@insmed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Hypertension
- Trans-pulmonary Biomarkers in Pulmonary Hypertension — Nashville, Tennessee
- Activity Monitoring in Pulmonary Hypertension — Nashville, Tennessee
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF — Tucson, Arizona
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) — Phoenix, Arizona
- A Study of Mosliciguat in PH-ILD — Phoenix, Arizona
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD — San Francisco, California
Explore by condition: All Pulmonary Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.